Teva Pharmaceutical Industries Limited

Yeda Research and Develpment & Co. Ltd

Antisense Therapeutics Limited

Ety Klinger

George Tachas

Shoshi Tessler

Mark Paul Diamond

Adrian Gilbert

Hussein Hallak

Sharon Cohen-Vered

Vera Weinstein

Hallak Hussein

Esmira Naftali

Sharon Cohen-vered

A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.

Low frequency glatiramer acetate therapy

A method for treating a patient suffering from multiple sclerosis, particularly a relapsing form of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE 1 to the patient, thereby treating the patient.

Methods for treating multiple sclerosis using antisense oligonucleotides

The subject invention provides a process for measuring the relative potency of a test batch of glatiramer acetate. In addition, the subject invention provides a process for preparing a batch of glatiramer acetate as acceptable for pharmaceutical use.

Process for the measurement of the potency of glatiramer acetate

The subject invention provides a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-;and a substituted &#x3b2;-cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition has a pH between 4 and 9, a process for preparation, and a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject the pharmaceutical composition.

Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

Growing community of inventors

Tel Aviv, Israel

Ety Klinger